We use cookies on our website to make it clear, useful and reliable.In order to achieve this and to provide certain personalised features we store a small amount of data about you. To learn more visit Cookies: How we use the information on our website. By navigating from the front page to other sections of our website, you are consenting to information being stored.
Final analysis of UK Phase 3 trials of Novavax's COVID-19 vaccine reveals it provides 100% protection against severe COVID-19.
By NIHR Wellcome King's Clinical Research Facility at 16 Mar 2021A 30-year-old man has spoken about his pride in aiding the national fightback against COVID-19 by taking part in vaccine research in south London.
By NIHR Wellcome King's Clinical Research Facility at 26 Feb 2021Interim analysis of study shows that the NIHR-supported Novavax COVID-19 vaccine is 89.3% effective at preventing COVID-19, including effectiveness against the new variants of concern.
By NIHR Wellcome King's Clinical Research Facility at 29 Jan 2021The first report from Public Health England's national SIREN study, supported at King's College Hospital by the King's CRF, has found that past COVD-19 infection provides 83% immunity for at least five months. However, some people may still carry the virus and transmit to other people.
By NIHR Wellcome King's Clinical Research Facility at 19 Jan 2021
The NIHR Maudsley Biomedical Research Centre (BRC) is part of the NIHR and hosted by South London and Maudsley NHS Foundation Trust in partnership with King's College London. We are part of King’s Health Partners Academic Health Sciences Centre.
© NIHR Maudsley Biomedical Research Centre 2024 | Website design by CSMB Design | All rights reserved.
